Lipids & metabolic liver disease
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction
Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 1.364 95% CI 1.145–1.625Authors' conclusion
Hepatic steatosis and advanced fibrosis have a substantial prevalence among patients with AMI. Both are associated with mortality, with an incrementally higher risk when advanced fibrosis ensues. Hepatic steatosis and fibrosis could help risk stratification of AMI patients beyond conventional risk factors.
Study context
- Population
- Patients presenting with AMI to a tertiary hospital, 2014–2021
- Participants
- 5,765 patients
- Exposure
- Hepatic steatosis vs no hepatic steatosis; advanced fibrosis vs no advanced fibrosis
- Outcome
- All-cause mortality
- Follow-up
- Median 2.7 years
Methodological detailssingle tertiary hospital
- Single tertiary hospital
Main finding
As reported in the abstract
Adjusted hazard ratio
1.364
95% CI 1.145–1.625
P = 0.001
By group
Hepatic steatosisvs No hepatic steatosis
aHR 1.364 (95% CI 1.145–1.625); P = 0.001
Observational data: associations, not effects.
Further findings
Prevalence
- Hepatic steatosis
- 24.8%
- Advanced fibrosis among those with hepatic steatosis
- 41.7%
Original publication
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction. Diabetes Obes Metab. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →